Navigation Links
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:5/15/2008

- Top Line Data Expected soon after CEA Trial data reports in third quarter

-

SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its acute coronary syndrome (ACS) study. The ACS study is one of three Phase 2 trials investigating VIA-2291, the company's lead product candidate in cardiovascular disease.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events (MACE) associated with inflammation, including heart attack and stroke.

"Completing enrollment in our second Phase 2 study is an important milestone for the company, and also represents the largest number of patients we have enrolled in a clinical trial to date," said Lawrence K. Cohen, PhD, chief executive officer of VIA Pharmaceuticals. "This trial will provide important data on VIA-2291's effect in the target population, patients with recent heart attack or unstable angina, and we remain on track to deliver data from this key trial later this year."

The ACS study, which enrolled 191 patients, is designed to establish dose and safety data in patients with ACS who have experienced a recent heart attack or unstable angina. The study includes measures of leukotrienes, biomarkers of inflammation, as well as medical imaging of the coronary vessels to evaluate the impact on plaque characteristics in a subset of patients. Patients i
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... ANGELES, May 1, 2015  CytRx Corporation (CYTR), ... oncology, today reported financial results for the three ... overview of recent accomplishments and upcoming milestones for ... several milestones in the early months of 2015, ... clinical trial of aldoxorubicin in patients with soft ...
(Date:5/1/2015)... 2015 The Institute for Healthcare Advancement (IHA) ... winners. The IHA Health Literacy Awards aim to encourage, ... the practice of educating or empowering organizations to deliver ... in three categories: innovative programs, published materials and research. ... award. In the area of innovative programs, ...
(Date:5/1/2015)... SUNNYVALE, Calif., May 1, 2015 Pharmacyclics, Inc. ... results for the quarter ended March 31, 2015, as ... merger with AbbVie Inc., no conference call will be held. ... the quarter ended March 31, 2015 increased to $206 ... 31, 2014. , Worldwide IMBRUVICA ® (ibrutinib) ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Institute for Healthcare Advancement Announces 2015 Award Winners 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25
... Reportlinker.com announces that a new market research ... Growth Hormone Deficiency Global Clinical ... http://www.reportlinker.com/p0567405/Growth-Hormone-Deficiency-Global-Clinical-Trials-Review-Q2-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development Growth Hormone ... Summary ...
... Details of advances in the use of stereotactic body ... high risk operable and inoperable cases were presented at the ... today, including significant improvements in survival of elderly lung cancer ... SBRT treatments. A study into survival rates ...
Cached Medicine Technology:Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 2Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 3Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 4Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 5Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 6Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 7Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 8Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 9Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 2Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 3Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 4Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 5Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 6
(Date:5/2/2015)... As one of only 30 Illinois companies to be ... and Recognition Program (SHARP) certification, Essentra Specialty Tapes ... Department of Labor to host this special event. ... the Occupational Safety and Health Administration’s (“OSHA”) Onsite Consultation ... or exceed all of the necessary regulations and standards, ...
(Date:5/2/2015)... “ ActOn ” was featured on NewsWatch ... at the latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... organizations to make a difference. , In this material world, ... that aren’t about money, which is why those things should ...
(Date:5/2/2015)... We are pleased to announce the ... as one of the Top Workplaces of 2015. , ... treatment field for their ethics and standards of excellence. ... continue their educational efforts. The Delray Recovery Center prides ... their purpose – to help individuals heal from the ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Kare Visits LLC. ... support for busy caregivers. Kare Visits offers relief for ... assisted living facilities. According to the Caregiver Action ... an average of 20 hours a week caring for an ... the cost to hire a nurse, a caregiver is now ...
(Date:5/2/2015)... 02, 2015 With the success that Veatch ... proud to welcome Neida Miranda and Alex Shields to the ... has over 41 years of combined experience working with dentists ... the dental field for 8 years. She was certified ... Texas. Customer service, positive attitude and showing the importance of ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2
... -- A test that profiles molecular biomarkers in blood could ... research shows. , The screen relies on changes in dozens ... unique pattern in people with Parkinson,s disease, according to a ... in New York City. , They published the findings in ...
... increases odds, study finds , , TUESDAY, March 11 ... glaucoma and those with high pressure in their eyes ... new study suggests. , "Glaucoma is one of the ... Stony Brook University in Stony Brook, N.Y., wrote as ...
... study found standard infection control was just as ... -- Universal screening for a common antibiotic-resistant bacteria ... reducing the rate of hospital-acquired infections in surgical ... methicillin-resistant Staphylococcus aureus (MRSA), is an ...
... 11 Edwards Lifesciences,Corporation (NYSE: EW ), ... advanced cardiovascular disease, is scheduled to participate in ... Marriott Copley Place,Hotel in Boston on Tuesday, March ... corporate vice president, chief,financial officer & treasurer, is ...
... Current recommendations for weight gain during pregnancy developed ... should be revised, according to an internationally recognized obesity ... and womens health at Saint Louis University. , The ... research on obesity during pregnancy, appears in the March ...
... (PHILADELPHIA) At a time when several U.S. ... sedative propofol during most screening colonoscopies, physicians at the ... an alternative way to administer the drug could both ... safer way to deliver optimal pain relief. , The ...
Cached Medicine News:Health News:First early-detection blood test for Parkinson's shows promise 2Health News:First early-detection blood test for Parkinson's shows promise 3Health News:Glaucoma May Boost Cardiovascular Death Risk in Blacks 2Health News:Universal Screening for MRSA in Hospitals Made Little Difference 2Health News:Universal Screening for MRSA in Hospitals Made Little Difference 3Health News:Edwards Lifesciences to Present at the Cowen and Company Annual Healthcare Conference 2Health News:Revise guidelines for weight gain during pregnancy, says Saint Louis U. obstetrician 2Health News:Penn research offers road map to safer pain control, cost savings during colonoscopies 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: